Evolution of Treatments of Prostate Cancer: From Biology to Current Advanced Technologies
Deadline for manuscript submissions: 30 April 2025 | Viewed by 3828
Prostate cancer (PC) is the most common cancer among men in the United States and most Western countries. PC has a particular propensity to metastasize to lymph nodes and bones. New molecular therapies are currently being developed to target specific steps of the metastatic process. However, to date, none of these therapies have radically improved survival. We need to understand the biology of the disease in order to develop combination therapies that address multiple pathways that support the progression of prostate cancer in order to improve survival and quality of life.
Technological advances such as intensity-modulated radiotherapy (IMRT) and stereotactic radiotherapy (SBRT) have improved the delivery of radiotherapy through modifications in dose fractionation and treatment target volumes. However, radiation oncologists have traditionally delivered homogenous doses for any given disease. Given the presence of heterogeneous tumor biology within a particular disease population, it is reasonable to hypothesize that there are subpopulations of patients for whom the therapeutic index of radiotherapy is not sufficiently optimized. This point likely explains the results of clinical trials in which uniform dose escalation has not proven to be consistently effective across multiple disease sites and stages of disease.
Yet, adaptive and modern planning techniques in the delivery of radiotherapy based on differences in intrinsic tumor biology have not been fully explored. For example, unique aspects of the tumor habitat, radiosensitivity, and microenvironment may allow for the development of an even more sophisticated method of adaptive treatment planning.
In summary, in this Special Issue, we will highlight some of the latest concepts in prostate cancer, including clinical advances, biological evolutions and current management strategies for optimal patient care with radiation therapy.
Dr. Fernando Munoz
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prostate cancer
- combination therapy
- radiation therapy
- intensity-modulated radiotherapy
- stereotactic radiotherapy
- clinical advances
- biological evolutions